Who’s Hired? ANI Names New CEO
ANI Pharmaceuticals Picks New Chief As Teva and Mylan Make Moves
ANI Pharmaceuticals has chosen its new president and CEO to replace interim chief Patrick Walsh who stepped in after the departure Arthur Przybyl earlier this year. Meanwhile, key personnel announcements have also been made by Teva and Mylan.
You may also be interested in...
Cipla’s generic of Merck & Co’s Proventil makes significant inroads in the US, with the Indian company confident that it has both a strong cost position and large capacity to take on competition. Pricing in the segment currently remains ‘respectable.’
A Cipla veteran and CEO of the firm’s India business and other executives have quit, though the Indian company maintains it has underlying strength and continued business momentum to sustain growth. ANI Pharmaceuticals in the US has snapped up one outgoing executive as president and CEO.
ANI revealed last month that long-serving company head Arthur Przybyl would be departing after 11 years at the top. The US-based player has just announced its interim chief as it reported first-quarter sales, following the landmark US portfolio acquisition from Amerigen in January, and made a major announcement for its full-year financial guidance.